Scribe Therapeutics vs ElevenLabs

Side-by-side comparison of AI visibility scores, market position, and capabilities

ElevenLabs leads in AI visibility (84 vs 29)
Scribe Therapeutics logo

Scribe Therapeutics

EmergingBioTech

CRISPR Epigenetic Gene Silencing (Cardiovascular)

Raised $100M Series B. Jennifer Doudna co-founder. Sanofi + Eli Lilly partnerships. STX-1150 (PCSK9 silencing via CasX-ELXR) IND projected mid-2026 — no permanent DNA edits.

AI VisibilityBeta
Overall Score
D29
Category Rank
#1 of 1
AI Consensus
59%
Trend
up
Per Platform
ChatGPT
30
Perplexity
37
Gemini
37

About

Scribe Therapeutics was co-founded by Jennifer Doudna — who shared the 2020 Nobel Prize in Chemistry for CRISPR-Cas9 invention — and develops the ELXR platform: a CasX-based epigenetic silencing system that reduces gene expression without making permanent DNA cuts. The company has raised $100 million in Series B financing with strategic partnerships with Sanofi and Eli Lilly. The lead program, STX-1150, targets PCSK9 for durable LDL-C reduction and is projected to receive an IND and enter human trials in mid-2026.

Full profile
ElevenLabs logo

ElevenLabs

ChallengerAI & Machine Learning

Voice AI

$500M Series D at $11B valuation (Feb 2026) — largest voice AI funding round ever. $330M ARR; 1M+ developers using the API. Enterprise customers: Deutsche Telekom, Revolut, Meta, Salesforce. Voices in 32 languages; real-time cloning from 1 second of audio.

AI VisibilityBeta
Overall Score
A84
Category Rank
#1 of 1
AI Consensus
64%
Trend
up
Per Platform
ChatGPT
79
Perplexity
89
Gemini
82

About

ElevenLabs was founded in 2022 by Piotr Dabkowski and Mati Staniszewski, two former Google and Palantir engineers who set out to break the language barrier using AI voice technology. The company specializes in AI-powered voice synthesis, cloning, and dubbing, enabling developers and enterprises to generate human-quality speech in over 30 languages. Its core technology combines deep learning models trained on massive speech datasets to produce natural-sounding voices indistinguishable from real humans.\n\nElevenLabs offers a suite of products including its flagship text-to-speech API, voice cloning tools, and an AI dubbing platform that localizes video content while preserving the speaker's original voice. Its products target a broad audience—from indie developers building audio apps to large enterprises deploying voice interfaces at scale. Key differentiators include ultra-low latency streaming synthesis, fine-grained voice customization, and a growing library of pre-built AI voices across accents and styles.\n\nElevenLabs has grown rapidly, surpassing $330M in annualized revenue and serving over 1 million developers. Enterprise clients include Deutsche Telekom, Spotify, and leading media companies. In February 2026, the company closed a $500M Series D at an $11B valuation, cementing its position as the market leader in AI voice. Its APIs power podcasts, audiobooks, video games, and customer service bots worldwide, making ElevenLabs the default infrastructure layer for AI-generated audio.

Full profile

AI Visibility Head-to-Head

29
Overall Score
84
#1
Category Rank
#1
59
AI Consensus
64
up
Trend
up
30
ChatGPT
79
37
Perplexity
89
37
Gemini
82
22
Claude
75
38
Grok
88

Key Details

Category
CRISPR Epigenetic Gene Silencing (Cardiovascular)
Voice AI
Tier
Emerging
Challenger
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Scribe Therapeutics
CRISPR Epigenetic Gene Silencing (Cardiovascular)
Only ElevenLabs
Voice AI

Integrations

Only ElevenLabs

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.